Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers

Key Inclusion Criteria: * Age ≥ 18 years at time of signing ICF * ECOG Performance Status of 0 or 1 * Histologic documentation of incurable, locally advanced or metastatic tumor of the type being evaluated in individual cohorts. * Adequate hepatic and renal function and adequate bone marrow reserve function. * For combination cohorts, participants must be eligible to receive the chemotherapy or targeted agent. * Ph1a only: No more than three prior therapeutic regimens. * Ph1b only: Must be FOLFIRI naïve participants and must have received only 1 prior therapeutic regimen administered for the treatment of cancer in the advanced/metastatic setting - OR - FOLFIRI naïve participants that only received adjuvant therapy who progressed within six months after completing adjuvant therapy, and are confirmed to have locally advanced/metastatic disease Key Exclusion Criteria: * Inability to comply with study and follow-up procedures. * Prior DR5 agonist therapy. * Concomitant use of agents well-known to cause liver toxicity. * Concomitant use of anti-cancer agents * Palliative radiation to bone metastases within 2 weeks prior to Day 1. * Major surgical procedure within 4 weeks prior to Day 1. * Untreated or active central nervous system (CNS) metastases (progressing or requiring anticonvulsants or corticosteroids for symptomatic control). Participants with a history of treated CNS metastases are eligible. * Prior use of any chemotherapeutic agent or small molecule inhibitors (SMI) wi…